New trial
Phase 2 trial of talquetamab, a GPRC5D x CD3 bispecific antibody, in multiple myeloma.
- Trial ID
- NCT06993675 on ClinicalTrials.gov
- Cancer type
- Multiple Myeloma
- Published in
- New in Oncology - June 16, 2025
This trial evaluates a response-adaptive consolidation strategy where MRD-positive patients after frontline induction receive talquetamab, with a switch to teclistamab if MRD negativity is not achieved. The study, sponsored by Noffar Bar in New Haven, aims to enhance MRD conversion and improve outcomes.
More in multiple myeloma
-
Trial result · Oct 22, 2026 · NCT04184050
MK-4002 (BCMA×CD3 trispecific T-cell engager) drives 63% ORR at 12 mg in heavily pretreated RRMM -
Trial result · Oct 15, 2026 · NCT04557150
Forimtamig (GPRC5D×CD3 2:1 bispecific) posts 72% ORR at optimized SC dosing—but toxicity caps escalation in RRMM -
New trial · Oct 15, 2026 · NCT06948084
Phase 2 daratumumab plus teclistamab is compared with DPd or DKd in high-risk, second-line multiple myeloma -
Trial result · Oct 1, 2026 · NCT03301220
Daratumumab (anti-CD38) cuts progression risk in Japanese high-risk SMM vs monitoring (AQUILA) -
Trial result · Sep 24, 2026 · NCT05469893
Teclistamab (BCMAxCD3 bispecific) drives 78% CR and 92% 2-year PFS in high-risk smoldering myeloma